Cuprina Holdings (Cayman) Ltd (CUPR) USD0.001

Sell:$5.48Buy:$5.90$0.04 (0.70%)

Prices delayed by at least 15 minutes
Sell:$5.48
Buy:$5.90
Change:$0.04 (0.70%)
Prices delayed by at least 15 minutes
Sell:$5.48
Buy:$5.90
Change:$0.04 (0.70%)
Prices delayed by at least 15 minutes

Company Information

About this company

Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.

Key people

Yong Qi Quek
Chief Executive Officer, Director
Tat Jing Chan
Chief Financial Officer
Carl Marc Baptista
Chief Technology Officer, Director
Peng Siew Lee
Non-Executive Director
Peng Kwang Teo
Non-Executive Director
Pee Keat Koh
Independent Director
Ivan Ng
Independent Director
Natasha Kaur Raina
Independent Director
Click to see more

Key facts

  • EPIC
    CUPR
  • Location
    Singapore
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    KYG2592E1026
  • Market cap
    $123.12m
  • Employees
    14
  • Shares in issue
    7.37m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.